A Pragmatic Approach to Prostate Cancer Screening
A pragmatic approach to prostate cancer screening has evolved over the years to address the harms associated with traditional screening methods. The introduction of PSA-based screening in the 1990s led to a decline in prostate cancer metastasis and mortality, but it also resulted in substantial harm...
Gespeichert in:
| Veröffentlicht in: | JAMA : the journal of the American Medical Association 2024-05, Vol.331 (17), p.1448-1450 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1450 |
|---|---|
| container_issue | 17 |
| container_start_page | 1448 |
| container_title | JAMA : the journal of the American Medical Association |
| container_volume | 331 |
| creator | Tosoian, Jeffrey J Penson, David F Chinnaiyan, Arul M |
| description | A pragmatic approach to prostate cancer screening has evolved over the years to address the harms associated with traditional screening methods. The introduction of PSA-based screening in the 1990s led to a decline in prostate cancer metastasis and mortality, but it also resulted in substantial harms due to overdiagnosis and overtreatment. In 2012, the US Preventive Services Task Force recommended against the use of PSA screening. However, longer-term outcomes from high-quality studies have provided better insights into the benefits of screening. Advances in understanding prostate cancer have also led to the adoption of active surveillance as a management strategy for favorable-risk cancers. Current guidelines recommend a narrowed diagnostic focus, with the use of MRI or biomarker testing to better define the risk of high-grade disease prior to biopsy. The use of biomarkers followed by MRI has shown promise in improving the detection of high-grade cancers. A recent study in Finland demonstrated the effectiveness of this approach, achieving a high yield of biopsy and reducing the overdiagnosis of low-grade disease. However, there are still knowledge gaps regarding the need for systematic biopsy in patients with positive or negative MRI results. |
| doi_str_mv | 10.1001/jama.2024.4089 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3034240466</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3034240466</sourcerecordid><originalsourceid>FETCH-LOGICAL-c323t-11722103a0e042c40e5706d2f78a6058e6cd219eb63bea1eaed6fb0123006ecf3</originalsourceid><addsrcrecordid>eNpdkEtLw0AQgBdRtFavHiXgxUvi7DObYym-oKCgnpfNZlJTmqTuJgf_vRtaPTiHGRi-GWY-Qq4oZBSA3m1sazMGTGQCdHFEZlRynXJZ6GMyAyh0mgstzsh5CBuIQXl-Ss64lpoyyWeELpJXb9etHRqXLHY731v3mQx97PZhsAMmS9s59Mmb84hd060vyElttwEvD3VOPh7u35dP6erl8Xm5WKWOMz6klOaMUeAWEARzAlDmoCpW59oqkBqVqxgtsFS8REvRYqXqEijjAApdzefkdr833vQ1YhhM2wSH263tsB-D4cAFEyCUiujNP3TTj76L10VKKsalimlOsj3l4mvBY212vmmt_zYUzCTTTDLNJNNMMuPA9WHtWLZY_eG_9vgPhOdtMA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3056235662</pqid></control><display><type>article</type><title>A Pragmatic Approach to Prostate Cancer Screening</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Tosoian, Jeffrey J ; Penson, David F ; Chinnaiyan, Arul M</creator><creatorcontrib>Tosoian, Jeffrey J ; Penson, David F ; Chinnaiyan, Arul M</creatorcontrib><description>A pragmatic approach to prostate cancer screening has evolved over the years to address the harms associated with traditional screening methods. The introduction of PSA-based screening in the 1990s led to a decline in prostate cancer metastasis and mortality, but it also resulted in substantial harms due to overdiagnosis and overtreatment. In 2012, the US Preventive Services Task Force recommended against the use of PSA screening. However, longer-term outcomes from high-quality studies have provided better insights into the benefits of screening. Advances in understanding prostate cancer have also led to the adoption of active surveillance as a management strategy for favorable-risk cancers. Current guidelines recommend a narrowed diagnostic focus, with the use of MRI or biomarker testing to better define the risk of high-grade disease prior to biopsy. The use of biomarkers followed by MRI has shown promise in improving the detection of high-grade cancers. A recent study in Finland demonstrated the effectiveness of this approach, achieving a high yield of biopsy and reducing the overdiagnosis of low-grade disease. However, there are still knowledge gaps regarding the need for systematic biopsy in patients with positive or negative MRI results.</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.2024.4089</identifier><identifier>PMID: 38581253</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Aged ; Biomarkers ; Biopsy ; Biopsy - adverse effects ; Biopsy - methods ; Cancer screening ; Early Detection of Cancer - adverse effects ; Early Detection of Cancer - methods ; Humans ; Kallikreins - blood ; Magnetic Resonance Imaging ; Male ; Mass Screening - adverse effects ; Mass Screening - methods ; Medical screening ; Metastases ; Middle Aged ; Overdiagnosis - prevention & control ; Overtreatment - prevention & control ; Predictive Value of Tests ; Prostate - diagnostic imaging ; Prostate - pathology ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnosis ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - pathology ; Randomized Controlled Trials as Topic ; Watchful Waiting</subject><ispartof>JAMA : the journal of the American Medical Association, 2024-05, Vol.331 (17), p.1448-1450</ispartof><rights>Copyright American Medical Association May 7, 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c323t-11722103a0e042c40e5706d2f78a6058e6cd219eb63bea1eaed6fb0123006ecf3</citedby><cites>FETCH-LOGICAL-c323t-11722103a0e042c40e5706d2f78a6058e6cd219eb63bea1eaed6fb0123006ecf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38581253$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tosoian, Jeffrey J</creatorcontrib><creatorcontrib>Penson, David F</creatorcontrib><creatorcontrib>Chinnaiyan, Arul M</creatorcontrib><title>A Pragmatic Approach to Prostate Cancer Screening</title><title>JAMA : the journal of the American Medical Association</title><addtitle>JAMA</addtitle><description>A pragmatic approach to prostate cancer screening has evolved over the years to address the harms associated with traditional screening methods. The introduction of PSA-based screening in the 1990s led to a decline in prostate cancer metastasis and mortality, but it also resulted in substantial harms due to overdiagnosis and overtreatment. In 2012, the US Preventive Services Task Force recommended against the use of PSA screening. However, longer-term outcomes from high-quality studies have provided better insights into the benefits of screening. Advances in understanding prostate cancer have also led to the adoption of active surveillance as a management strategy for favorable-risk cancers. Current guidelines recommend a narrowed diagnostic focus, with the use of MRI or biomarker testing to better define the risk of high-grade disease prior to biopsy. The use of biomarkers followed by MRI has shown promise in improving the detection of high-grade cancers. A recent study in Finland demonstrated the effectiveness of this approach, achieving a high yield of biopsy and reducing the overdiagnosis of low-grade disease. However, there are still knowledge gaps regarding the need for systematic biopsy in patients with positive or negative MRI results.</description><subject>Aged</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Biopsy - adverse effects</subject><subject>Biopsy - methods</subject><subject>Cancer screening</subject><subject>Early Detection of Cancer - adverse effects</subject><subject>Early Detection of Cancer - methods</subject><subject>Humans</subject><subject>Kallikreins - blood</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Mass Screening - adverse effects</subject><subject>Mass Screening - methods</subject><subject>Medical screening</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Overdiagnosis - prevention & control</subject><subject>Overtreatment - prevention & control</subject><subject>Predictive Value of Tests</subject><subject>Prostate - diagnostic imaging</subject><subject>Prostate - pathology</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Watchful Waiting</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkEtLw0AQgBdRtFavHiXgxUvi7DObYym-oKCgnpfNZlJTmqTuJgf_vRtaPTiHGRi-GWY-Qq4oZBSA3m1sazMGTGQCdHFEZlRynXJZ6GMyAyh0mgstzsh5CBuIQXl-Ss64lpoyyWeELpJXb9etHRqXLHY731v3mQx97PZhsAMmS9s59Mmb84hd060vyElttwEvD3VOPh7u35dP6erl8Xm5WKWOMz6klOaMUeAWEARzAlDmoCpW59oqkBqVqxgtsFS8REvRYqXqEijjAApdzefkdr833vQ1YhhM2wSH263tsB-D4cAFEyCUiujNP3TTj76L10VKKsalimlOsj3l4mvBY212vmmt_zYUzCTTTDLNJNNMMuPA9WHtWLZY_eG_9vgPhOdtMA</recordid><startdate>20240507</startdate><enddate>20240507</enddate><creator>Tosoian, Jeffrey J</creator><creator>Penson, David F</creator><creator>Chinnaiyan, Arul M</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20240507</creationdate><title>A Pragmatic Approach to Prostate Cancer Screening</title><author>Tosoian, Jeffrey J ; Penson, David F ; Chinnaiyan, Arul M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c323t-11722103a0e042c40e5706d2f78a6058e6cd219eb63bea1eaed6fb0123006ecf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Biopsy - adverse effects</topic><topic>Biopsy - methods</topic><topic>Cancer screening</topic><topic>Early Detection of Cancer - adverse effects</topic><topic>Early Detection of Cancer - methods</topic><topic>Humans</topic><topic>Kallikreins - blood</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Mass Screening - adverse effects</topic><topic>Mass Screening - methods</topic><topic>Medical screening</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Overdiagnosis - prevention & control</topic><topic>Overtreatment - prevention & control</topic><topic>Predictive Value of Tests</topic><topic>Prostate - diagnostic imaging</topic><topic>Prostate - pathology</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Watchful Waiting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tosoian, Jeffrey J</creatorcontrib><creatorcontrib>Penson, David F</creatorcontrib><creatorcontrib>Chinnaiyan, Arul M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tosoian, Jeffrey J</au><au>Penson, David F</au><au>Chinnaiyan, Arul M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Pragmatic Approach to Prostate Cancer Screening</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><addtitle>JAMA</addtitle><date>2024-05-07</date><risdate>2024</risdate><volume>331</volume><issue>17</issue><spage>1448</spage><epage>1450</epage><pages>1448-1450</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><abstract>A pragmatic approach to prostate cancer screening has evolved over the years to address the harms associated with traditional screening methods. The introduction of PSA-based screening in the 1990s led to a decline in prostate cancer metastasis and mortality, but it also resulted in substantial harms due to overdiagnosis and overtreatment. In 2012, the US Preventive Services Task Force recommended against the use of PSA screening. However, longer-term outcomes from high-quality studies have provided better insights into the benefits of screening. Advances in understanding prostate cancer have also led to the adoption of active surveillance as a management strategy for favorable-risk cancers. Current guidelines recommend a narrowed diagnostic focus, with the use of MRI or biomarker testing to better define the risk of high-grade disease prior to biopsy. The use of biomarkers followed by MRI has shown promise in improving the detection of high-grade cancers. A recent study in Finland demonstrated the effectiveness of this approach, achieving a high yield of biopsy and reducing the overdiagnosis of low-grade disease. However, there are still knowledge gaps regarding the need for systematic biopsy in patients with positive or negative MRI results.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>38581253</pmid><doi>10.1001/jama.2024.4089</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-7484 |
| ispartof | JAMA : the journal of the American Medical Association, 2024-05, Vol.331 (17), p.1448-1450 |
| issn | 0098-7484 1538-3598 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3034240466 |
| source | MEDLINE; American Medical Association Journals |
| subjects | Aged Biomarkers Biopsy Biopsy - adverse effects Biopsy - methods Cancer screening Early Detection of Cancer - adverse effects Early Detection of Cancer - methods Humans Kallikreins - blood Magnetic Resonance Imaging Male Mass Screening - adverse effects Mass Screening - methods Medical screening Metastases Middle Aged Overdiagnosis - prevention & control Overtreatment - prevention & control Predictive Value of Tests Prostate - diagnostic imaging Prostate - pathology Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - pathology Randomized Controlled Trials as Topic Watchful Waiting |
| title | A Pragmatic Approach to Prostate Cancer Screening |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T14%3A13%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Pragmatic%20Approach%20to%20Prostate%20Cancer%20Screening&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Tosoian,%20Jeffrey%20J&rft.date=2024-05-07&rft.volume=331&rft.issue=17&rft.spage=1448&rft.epage=1450&rft.pages=1448-1450&rft.issn=0098-7484&rft.eissn=1538-3598&rft_id=info:doi/10.1001/jama.2024.4089&rft_dat=%3Cproquest_cross%3E3034240466%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3056235662&rft_id=info:pmid/38581253&rfr_iscdi=true |